Literature DB >> 8370321

Pharmacokinetic profile of fosfomycin trometamol.

T Bergan1, S B Thorsteinsson, E Albini.   

Abstract

The pharmacokinetics of fosfomycin trometamol has been assessed in 12 healthy volunteers given oral doses of 2, 3, and 4 g of fosfomycin and 3 g intravenously of fosfomycin as fosfomycin sodium, all in the fasting state. The assay was microbiological (Proteus mirabilis ATCC 21100). There was a gradual rise in both peak serum concentrations and total area under the curve by rising oral doses, from 16.0 mg/l and 106.7 mg x h/l, after 2 g to 30.9 mg/l and 189.7 mg x h/l after 4 g respectively. The serum half-life was 4 h after the oral doses and 2.1 h after the intravenous dose. After the oral doses, the amounts excreted in urine in the active form ranged from 36 to 40% compared to 93% after the intravenous dose. The bioavailability was slightly below 40%. Concentrations in urine covers the usual urinary tract pathogens after oral doses of 2, 3, and 4 g.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370321     DOI: 10.1159/000239140

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  23 in total

1.  An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH.

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-09       Impact factor: 3.267

2.  Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Authors:  E Wenzler; E J Ellis-Grosse; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 4.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

Review 5.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

6.  Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic Enterobacteriaceae.

Authors:  Maria Loose; Isabell Link; Kurt G Naber; Florian M E Wagenlehner
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

7.  Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies.

Authors:  Tanya Zapolskaya; Sarah Perreault; Dayna McManus; Jeffrey E Topal
Journal:  Support Care Cancer       Date:  2018-01-10       Impact factor: 3.603

Review 8.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

9.  Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women.

Authors:  G Elhanan; H Tabenkin; R Yahalom; R Raz
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 10.  'Old' antibiotics for emerging multidrug-resistant bacteria.

Authors:  Phillip J Bergen; Cornelia B Landersdorfer; Hee Ji Lee; Jian Li; Roger L Nation
Journal:  Curr Opin Infect Dis       Date:  2012-12       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.